Develpoment and evaluation of validation characteristics of the quantitative determination method for loratadine in the syrup
DOI:
https://doi.org/10.24959/nphj.14.1930Keywords:
validation, pharmaceutical analysis, spectrophotometry, loratadine, syrupAbstract
The problem of allergic diseases growth is quite urgent in the world: up to 40% of the adult population and 10-12% of children suffer from this disease. According to the data of epidemiologic studies, the most widespread diseases are bronchial asthma, allergic rhinitis and atopic dermatitis. Among avaliable antihistamine drugs loratadine is one of the most common, it is used for elimination of allergic manifestations both in adults and children. Since for adherence to specifications of the technological process when manufacturing medicines it is necessary to have the developed and validated methods for the quality control, we have proposed a new method for quantitative determination of loratadine in the syrup by the spectrophotometric method. When studying the character of loratadine spectra in alcohol, 0.1 М solution of hydrochloric acid and 0.1 М solution of sodium hydroxide it has been found that the best solvent is 0.1 М solution of hydrochloric acid. The assay was performed by the standard method at the wavelength of 278 nm. The effect of excipients of the syrup was removed by their extraction with ether. The validation characteristics of the method (robustness, accuracy and convergence, linearity, precision) have been determined. The evaluation of such validation characteristics obtained as accuracy (0.18% ≤ 1.54%), convergence (1.6% ≤ 3.2%), intermediate precision (0.62% ≤ 4.80%) allows to control the quality of loratadine in other laboratories according to the method recommended.
References
Багирова В.Л., Гризодуб А.И., Чибиляев Т.Х. и др. Руководство по валидации методик анализа лекарственных средств / Под ред. Н.В.Юргеля. – М.: Фарм. пром., 2007. – 58 с.
Гризодуб А.И. // Фармаком. – 2002. – №3. – С. 42-50.
Державна фармакопея України / Державне підприємство «Науково-експертний фармакопейний центр». – 1-е вид. – Доп. 1. – Х.: РІРЕГ, 2004. – 494 с.
Державна фармакопея України / Державне підприємство «Науково-експертний фармакопейний центр». – 1-е вид. – Доп. 2. – Х.: РІРЕГ, 2008. – 620 с.
Кейтлин И.М., Мазулин А.В. // Запорож. мед. журн. – 2008. – №6. – С. 48-50.
British Pharmacopoeia. – London. The Stationary Office. – 2009. – Vol. 1-2. – 10952 p.
Clarke’s analysis of drugs and poisons: in pharmaceuticals, body fluids and postmortem material / Ed. A.C.Moffat, M.D.Osselton, B.Widdop, J.Watts. – London: Pharmaceutical Press, 2011. – 4-th ed. – 2473 p.
Cuvill A., Mullol J., Bartra J. et al. // J. Investig. Allergol. Clin. Immunol. – 2006. – Vol. 16 (1). – P. 3-12.
European Pharmacopoeia. – 6-th ed., 2007.
Fatatry H.M., Hammad S., Mabrouk M.M., Wahbi A.A. // J. Pharm. Biomed. Anal. – 2003. – Vol. 33, №4. – Р. 597-604.
United States Pharmacopoeia 32-NF 27, 2009.
Downloads
Published
Issue
Section
License
Copyright (c) 2014 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
